Why Incyte’s ESMO 2026 oncology readouts matter for its expanding Phase 3 pipeline
Incyte’s ESMO 2026 programme puts three investigational cancer assets under scrutiny across pancreatic, colorectal and ovarian tumours.
Pharma & Biotech
Pharma & Biotech
How Incyte’s retifanlimab approval could reshape first-line therapy for advanced anal cancer in Europe
European regulators approve retifanlimab for advanced anal cancer. Discover what this means for immunotherapy treatment strategies in rare oncology today.